The Prevalence of P53 Mutations in Laryngeal Cancer in Kerman


1 Assistant Professor of Ear, Nose and Throat, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran

2 Assistant Professor of Medical Genetics, Physiology Research Center & Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran

3 Clinical Pathologist, Shafa Hospital, Kerman University of Medical Sciences, Kerman, Iran


Background &Aims: Laryngeal cancer is the second common cancer of respiratory tract, following the lung cancer. Carcinogenesis is a complex multistage process; molecular genetics has provided the evidence that activation of proto-oncogene and loss or inactivation of tumor suppressor genes (TSG) are involved in a large number of malignancies. One of the earliest significant tumor suppressor genes identified in head and neck squamous cell carcinoma (HNSCC) was P53 have a role in growth suppression activities. Thus, when P53 is deleted or silenced, the cell develops a selective growth advantage and becomes a cancer. Mutations in P53 are correlated with poorer survival and response to treatment. The aim of this study was to survey the prevalence of P53 gene mutation in patients with laryngeal cancer and to select an appropriate method of treatment. Methods: The samples were 52 patients with laryngeal cancer diagnosis have been treated by surgery. Investigation of TP53 mutation where performed by multiple ligation probe amplification (MLPA) technique which analyze the full length of gene from exon 1 to 12. Results: The TP53 mutation was discovered in 80.8 percent of samples. By contrast between two main forms of mutation (i.e. deletions and duplications), we found that the deletions mostly occurred within exons 1, 3, 6, 9 and 12 by 59.6 percent and duplications observed in exons 1, 2, 7, 8 and 11 by 21.2 percent. Conclusion: Considering our results and reminding this fact that nowadays the definitive diagnosis of laryngeal cancer is made using biopsy and pathology techniques, we suggest that all biopsy specimens should be tested and those confirmed positive for TP53 mutations need some further decisions by physicians.